Trutakna (atacicept) has cleared the FDA's accelerated approval bar in IgA nephropathy on the strength of a -52%±5% UPCR reduction through 96 weeks — a surrogate endpoint decision, not a clinical outcomes decision. [1] That distinction carries weight: the press release frames eGFR stabilization as a competitive differentiator against Voyxact (sparsentan), but the 52-week eGFR data cited sit inside ORIGIN 3's open-label extension period, after only 36 weeks of randomized, blinded treatment. When every patient is receiving atacicept 150 mg and there is no concurrent control arm, attributing the mean annualized eGFR slope of -0.6±0.5 mL/min/1.73 m² per year solely to drug effect — rather than to natural history, regression to the mean, or selection of tolerators — is not straightforward. [1] The comparison to sparsentan's -2.7 mL/min/1.73 m² per year (PROTECT Phase 3 RCT, active-controlled against irbesartan throughout) is indirect and design-confounded; PROTECT maintained blinding and an active comparator at the 52-week mark, a materially higher evidentiary standard. [2] Similarly, budesonide (Kinpeygo, NefIgArd Phase 3 RCT, placebo-controlled) showed a 2-year eGFR slope difference of 1.82 mL/min/1.73 m² per year versus placebo. [2] Neither precedent clears the mechanistic-fit bar for atacicept — sparsentan targets dual ETA/AT1 hemodynamic pathways; budesonide acts via gut-associated lymphoid tissue corticosteroid immunosuppression; atacicept inhibits BAFF and APRIL to suppress pathogenic B-cell-derived IgA production. [1][3] Regulatory pathway precedent (proteinuria surrogate → eGFR confirmatory → hard outcomes post-marketing) is transferable from both approvals, but no mechanistic precedent for BAFF/APRIL inhibition in IgAN exists. [4] Atacicept's most direct mechanistic competitor is telitacicept, a BLyS/APRIL dual-target inhibitor that demonstrated an SMD of -5.21 (95% CI -7.55 to -2.87) for proteinuria reduction in a network meta-analysis of IgAN patients — superior to atacicept in that indirect comparison, with no head-to-head trial reported. [5] The -66%±2% reduction in galactose-deficient IgA1 (Gd-IgA1) through 96 weeks validates pathway engagement and is a genuine mechanistic strength absent from both approved peers, but Gd-IgA1 is not itself a regulatory endpoint. [1] The sharpest remaining risk is the confirmatory trial obligation: accelerated approval in IgAN now carries an explicit expectation that post-marketing studies demonstrate benefit on hard kidney outcomes — ESRD, sustained eGFR decline ≥40% or ≥50%, or kidney failure — and failure to confirm converts the approval to a withdrawal.
ORIGIN 3's randomized, blinded phase covered only 36 weeks; the emphasized 52-week eGFR data fall within the open-label extension where all patients received atacicept 150 mg, limiting causal attribution. [1] Proteinuria reduction (-52%±5%) supports accelerated approval but hard outcomes remain unconfirmed. [1]
| Indication | IgA nephropathy |
| Drug | Trutakna |
| Company | Vera Therapeutics |
| Trial Phase | Phase 3 |
| Trial Acronym | ORIGIN 3 |
| Category | Clinical Trial Event |
| Sub Category | Topline Results Positive |
| Therapeutic Area | Nephrology & Urology |
| Primary Endpoint | Proteinuria |
| Key Efficacy Measure | Estimated Glomerular Filtration Rate (eGFR) |
| Follow-up Duration | 52 weeks, 60 weeks, 72 weeks |
| Regulatory Designation | Accelerated Approval |
| Regulatory Agency | FDA |
| Comparator Drugs | Voyxact, Fabhalta |
| Data Presentation | medical congress |
| Trutakna Approval Month | July 2026 |
| Fabhalta Approval Date | August 2024 (accelerated), July 2026 (full) |
| Data Source Document | Summary Basis for Approval document |
Vera's Trutakna Shows Promising Kidney Function, Rivals Voyxact
Vera Therapeutics' Trutakna, which received accelerated approval from the FDA last month, has demonstrated promising kidney function improvements, positioning it as a strong competitor to Otsuka Pharmaceuticals' Voyxact. Data from the pivotal Phase 3 ORIGIN 3 study, detailed in the FDA's Summary Basis for Approval document, showed 'impressive' stabilization in estimated glomerular filtration rate (eGFR) through 52 weeks. While Trutakna's accelerated approval was based on proteinuria, analysts noted its eGFR trajectory compares favorably to Voyxact, alleviating prior investor concerns about its ability to compete in the IgA nephropathy market.
- In the pivotal Phase 3 ORIGIN 3 study, Vera Therapeutics' Trutakna demonstrated "impressive" stabilization in estimated glomerular filtration rate (eGFR) through 52 weeks. This finding, highlighted in the FDA's Summary Basis for Approval document, suggests Trutakna's potential to slow the decline of kidney function in IgA nephropathy patients, a benefit previously considered unique to Otsuka's Voyxact.
- Trutakna's accelerated approval by the FDA was primarily based on improvements in proteinuria, a recognized biomarker for IgA nephropathy. Although the FDA acknowledged "promising" eGFR improvements, the agency deemed the data insufficient for definitive conclusions regarding kidney benefits, noting it came from a "limited number of patients."
- Analysts observed that Trutakna's eGFR trajectory, including an initial "bump" at four weeks and subsequent stabilization through 52, 60, and 72 weeks, closely matches that of Otsuka's Voyxact. This favorable comparison is seen as reassuring for investors, suggesting Trutakna's long-term eGFR profile could track similarly to its competitor, thereby strengthening its position against Voyxact and Novartis' Fabhalta in the IgAN market.
Trutakna's ORIGIN 3 Data: Stabilizing Kidney Function in IgAN
The ALIGN Trial (NCT04573478) evaluated atrasentan 0.75 mg orally daily versus placebo in patients with IgA nephropathy. On the primary efficacy endpoint, the geometric mean percentage change in urinary protein-to-creatinine ratio (UPCR) at Week 36 was −38.1% with atrasentan versus −3.1% with placebo, yielding a statistically significant between-group difference of −36.1 percentage points (95% CI, −44.6 to −26.4; P<0.001). From a safety perspective, the overall rate of adverse events was comparable between groups. Fluid retention was reported in 11.2% of atrasentan-treated patients versus 8.2% in the placebo group, though no cases resulted in treatment discontinuation, and no apparent cases of cardiac failure or severe edema were observed.
The PROTECT Trial (NCT03762850) assessed sparsentan — a single-molecule dual endothelin-angiotensin receptor antagonist — against the maximum labeled dose of irbesartan across 404 randomized patients. Sparsentan demonstrated meaningful proteinuria reduction and preservation of kidney function relative to irbesartan. Among patients achieving complete remission by Week 110 (CR110; 21% of the cohort), the absolute eGFR change was substantially attenuated compared to non-responders (−4.0 vs. −8.6 mL/min/1.73 m²), with a markedly slower annual rate of eGFR decline (−0.7 vs. −4.2 mL/min/1.73 m²/year). Only 1% of CR110 patients reached the composite kidney endpoint versus 14% of non-CR patients. On safety, CR110 patients had a higher likelihood of hypotension-related adverse events but were less likely to experience hypertension-related events. Treatment discontinuation due to adverse events was notably lower in CR110 patients (4%) compared to non-CR patients (11%).
A third crossover study evaluating atrasentan (NCT05834738) specifically examined its additive effect in patients already receiving background therapy with both a RAS inhibitor and an SGLT2 inhibitor. Atrasentan 0.75 mg once daily produced a between-group difference in geometric mean UPCR change of −25.3% at Week 12 (95% CI, −36.8 to −11.7; P<0.001), with a consistent treatment difference of −26.4% observed at Week 24. The safety profile was favorable: fluid retention events were uncommon and required no hospitalizations, there were no treatment-related discontinuations, and no deaths occurred. Only one unrelated serious adverse event was reported across the study period.
Unpacking ORIGIN 3: Design and Endpoints for Trutakna
The PROTECT trial represents the most rigorously designed registrational study in IgA nephropathy (IgAN), establishing a benchmark for endpoint selection and comparator design in this space. Alongside PROTECT, a broader body of evidence — spanning retrospective cohorts, real-world databases, and randomized exercise therapy trials — has collectively shaped the understanding of clinically meaningful outcomes in IgAN. The table below summarizes key design parameters and endpoints across these studies.
| Trial / Study | Design | Population | Intervention | Primary Endpoint | Key Secondary Endpoints |
|---|---|---|---|---|---|
| PROTECT (Sparsentan vs Irbesartan) | International, randomized, double-blind, active-controlled; 134 sites, 18 countries | Adults ≥18 years; biopsy-proven IgAN; proteinuria ≥1.0 g/day despite maximized RASi ≥12 weeks (N=404, 1:1) | Sparsentan 400 mg QD vs Irbesartan 300 mg QD | Change from baseline in UPCR (24-hour urine) at Week 36 | Treatment-emergent adverse events |
| Exercise Therapy RCT (UMIN000038415) | Multi-center randomized controlled trial; 12-week observation + 24-week intervention | CKD patients post-renal biopsy (≤3 months); IgAN subgroup n=16 (N=46 randomized) | Home-based aerobic exercise 3×/week + resistance training 2×/week vs usual care | Creatinine-based eGFR or serum cystatin C–based eGFR | Urinary protein; exercise tolerance |
| MMF vs Cyclophosphamide Study | Retrospective; median follow-up 30 months (max 96 months) | IgAN patients with ≥1 active pathological lesion (endocapillary proliferation, cellular crescents, or fibrinoid necrosis); N=119 | Prednisone alone (n=48) vs MMF + prednisone (n=40) vs CTX + prednisone (n=31) | Renal survival | Incidence of proteinuria remission |
| Corticosteroid Timing Study | Retrospective; propensity score–matched cohorts (N=191 matched from 268) | IgAN patients treated with corticosteroids >3 months within 3 years of kidney biopsy | Early corticosteroid therapy (≤30 days post-biopsy) vs delayed therapy (>30 days) | Composite renal outcome: >50% eGFR reduction, ESKD, or renal death | eGFR decline >30% or >40%; eGFR slope; time-averaged proteinuria |
| J-CKD-DB-Ex Proteinuria Reduction Study | Retrospective observational; real-world database; mean observation ~2,040 days | Adult IgAN patients; baseline UPCR ≥0.5 g/gCr; eGFR ≥30 mL/min/1.73 m² (N=385) | ≥30% UPCR reduction at 9–12 months post-index (n=245) vs non-reduction group | Composite of 40% eGFR decline from baseline or onset of CKD stage G5 | eGFR slope |
Navigating the IgAN Landscape: Trutakna vs. Voyxact and Fabhalta
Over the past five years, the treatment landscape for IgA nephropathy (IgAN) has undergone a fundamental transformation, shifting decisively away from renin-angiotensin-aldosterone system (RAAS) inhibitors as the primary therapeutic backbone toward a diverse array of targeted, disease-modifying agents. SGLT-2 inhibitors were among the first to demonstrate meaningful nephroprotection in this population. In the DAPA-CKD trial, dapagliflozin 10 mg reduced the primary composite renal outcome to 4% versus 15% in the placebo arm among 270 IgAN participants (HR 0.29; 95% CI 0.12–0.73), with a mean eGFR decline of −3.5 versus −4.7 mL/min/1.73 m²/year and a 26% relative reduction in urinary albumin-to-creatinine ratio — all within a favorable safety profile. Concurrently, sparsentan, a dual endothelin-angiotensin receptor antagonist, demonstrated in the PROTECT trial a 41% relative proteinuria reduction versus irbesartan at 36 weeks (geometric LSM percent change: −49.8% vs. −15.1%; LSM ratio 0.59; 95% CI 0.51–0.69; p<0.0001), sustained through 110 weeks with proteinuria remaining 40% lower and a statistically significant attenuation of eGFR decline (chronic slope difference: 1.1 mL/min/1.73 m²/year; 95% CI 0.1–2.1; p=0.037).
Targeted-release budesonide (Nefecon) introduced a gut-centric mechanistic approach by acting at the mucosal level to interrupt the pathogenic galactose-deficient IgA1 axis. In the NefIgArd trial, nine months of Nefecon reduced UPCR by 27% relative to placebo and preserved eGFR with a 3.87 mL/min/1.73 m² advantage at nine months. Two-year data reinforced these findings, with a time-weighted average eGFR change of −2.47 mL/min/1.73 m² for Nefecon versus −7.52 mL/min/1.73 m² for placebo — a statistically significant treatment benefit of 5.05 mL/min/1.73 m² (95% CI 3.24–7.38; p<0.0001). In the B-cell cytokine space, atacicept — a fusion protein inhibiting both BAFF and APRIL — demonstrated sustained 96-week reductions in Gd-IgA1 (−66% ± 2%), hematuria prevalence (−75%; 95% CI −87 to −59), and UPCR (−52% ± 5%), with a mean annualized eGFR slope of only −0.6 ± 0.5 mL/min/1.73 m², alongside a generally well-tolerated safety profile.
Collectively, these data reflect a broader paradigm shift in IgAN management, now encompassing four principal biological categories: anti-CD20 monoclonal antibodies, anti-BLyS or APRIL monoclonal antibodies, dual BLyS/APRIL inhibitors (including telitacicept and atacicept), and complement-targeting agents such as narsoplimab and eculizumab. This mechanistic diversification signals the transition toward a precision medicine framework in IgAN — one where therapeutic selection can be increasingly informed by pathophysiological endotype, biomarker profile, and stage of disease progression, offering clinicians and strategic teams a substantially expanded, evidence-based armamentarium.
Trutakna's eGFR Trajectory: A New Benchmark in IgA Nephropathy
The recent accelerated approval of Vera Therapeutics' Trutakna (atacicept) for IgA nephropathy (IgAN) marks a pivotal moment, not just for the company, but for the broader treatment paradigm of this chronic, progressive kidney disease. While the initial approval was based on its ability to reduce proteinuria, a well-established surrogate marker for disease progression, the newly highlighted data on estimated glomerular filtration rate (eGFR) stabilization is particularly compelling. This 'impressive' eGFR trajectory, observed through 52 weeks in the pivotal Phase 3 ORIGIN 3 study, directly addresses the critical goal of preserving kidney function and delaying the progression to end-stage renal disease (ESKD).
IgAN is driven by the overproduction of pathogenic galactose-deficient IgA1 (Gd-IgA1), a process significantly influenced by A Proliferation-Inducing Ligand (APRIL) and B-cell activating factor (BAFF). Atacicept, by inhibiting both APRIL and BAFF, targets this underlying immune dysregulation, leading to reductions in Gd-IgA1 and subsequent improvements in proteinuria and, crucially, stabilization of eGFR. This dual mechanism of action and the resulting eGFR data provide a strong competitive edge, potentially setting a new benchmark for efficacy expectations in the IgAN market.
However, the journey for Trutakna is not without its considerations. As an accelerated approval, full market authorization hinges on the successful completion of a postmarketing confirmatory trial. Furthermore, the IgAN therapeutic landscape is rapidly evolving, with several other anti-APRIL therapies and novel mechanisms in various stages of development. This intensifying competition means that long-term safety and efficacy data, particularly regarding sustained eGFR benefits, will be paramount for Trutakna to maintain its differentiated position and secure enduring market share. The ability to demonstrate consistent, long-term kidney protection will be key to solidifying its role as a foundational therapy in IgAN management.
Frequently Asked Questions
References
- [1] Hou W, Yang H et al.. Long-term evaluation of the timing of corticosteroid therapy in an IgA nephropathy cohort. Clinical kidney journal. 2025 May. 40322679
- [2] Barratt J, Lafayette R et al.. Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy. Kidney international. 2023 Feb. 36270561
- [3] Zhang Y, Lin Y et al.. Nefecon in IgA nephropathy: real-world renal efficacy, safety profile, and treatment response from a 9-month retrospective cohort analysis. International urology and nephrology. 2026 Aug. 41484518
- [4] Heerspink HJL, Jardine M et al.. Atrasentan in Patients with IgA Nephropathy. The New England journal of medicine. 2025 Feb 6. 39460694
- [5] Schanz M, Seikrit C et al.. First real-world evidence of sparsentan efficacy in patients with IgA nephropathy treated with SGLT2 inhibitors. Clinical kidney journal. 2025 Jan. 39872637
- [6] Heerspink HJL, Radhakrishnan J et al.. Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial. Lancet (London, England). 2023 May 13. 37015244
- [7] Wheeler DC, Toto RD et al.. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney international. 2021 Jul. 33878338
- [8] Barratt J, Barbour SJ et al.. Long-Term Results from an Open-Label Extension Study of Atacicept for the Treatment of IgA Nephropathy. Journal of the American Society of Nephrology : JASN. 2025 Apr 1. 39462308
- [9] Liang Y, Zhang J et al.. Retrospective study of mycophenolate mofetil treatment in IgA nephropathy with proliferative pathological phenotype. Chinese medical journal. 2014. 24384432
- [10] Yang C, Liang S et al.. Single-nephron eGFR and kidney function decline in IgA nephropathy. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2026 Jul 31. 41627293
- [11] Champtiaux N, Lioté F et al.. Spondyloarthritis-Associated IgA Nephropathy. Kidney international reports. 2020 Jun. 32518863
- [12] Heerspink HJL, Jardine M et al.. Study Design and Baseline Characteristics of ALIGN, a Randomized Controlled Study of Atrasentan in Patients With IgA Nephropathy. Kidney international reports. 2025 Jan. 39810771
- [13] Sharma I, Panta R. Emerging Therapies in IgA Nephropathy: From A Proliferation-Inducing Ligand (APRIL) and B-cell Activating Factor (BAFF) Inhibitors to Precision Medicine. Cureus. 2025 Dec. 41573494
- [14] Kimura T, Washida N et al.. A multi-center randomized controlled trial to investigate potential effects of exercise therapy on renal function stratified by renal disorders and renal pathology: beneficial or harmful effect in immunoglobulin a nephropathy. Clinical and experimental nephrology. 2024 Jun. 38402501
- [15] Rovin BH, Barratt J et al.. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial. Lancet (London, England). 2023 Dec 2. 37931634
- [16] Yoshida T, Takei T et al.. Risk factors for progression in patients with early-stage chronic kidney disease in the Japanese population. Internal medicine (Tokyo, Japan). 2008. 18981628
- [17] Barratt J, Rovin B et al.. IgA Nephropathy Patient Baseline Characteristics in the Sparsentan PROTECT Study. Kidney international reports. 2023 May. 37180506
- [18] Heerspink HJL, Noronha IL et al.. Efficacy and Safety of Atrasentan in Patients with IgA Nephropathy Receiving Sodium-Glucose Cotransporter 2 Inhibitors: Placebo-Controlled, Crossover Trial. Journal of the American Society of Nephrology : JASN. 2026 Mar 29. 41904616
- [19] Imai N, Shirai S et al.. Long-term prognosis of IgA nephropathy presenting with minimal or no proteinuria: A single center experience. Indian journal of nephrology. 2016 Mar-Apr. 27051134
- [20] Smeijer JD, Kohan DE et al.. Endothelin receptor antagonists in chronic kidney disease. Nature reviews. Nephrology. 2025 Mar. 39643698
Contact Us
Address
One Research Ct, Suite 450
Rockville, MD 20850
For General Inquiry
info@pienomial.com
